Table 3 Changes in clinical laboratory data during the observation period
From: Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients
Follow-up period (months) | |||||
|---|---|---|---|---|---|
Baseline | 6 | 12 | 16 | p* | |
Hemoglobin (g/dL) | 10.9 ± 0.8 | 10.7 ± 0.9 | 10.3 ± 0.8 | 10.4 ± 0.7 | 0.23 |
Hematocrit (%) | 32.6 ± 2.2 | 32.5 ± 2.8 | 30.9 ± 1.9 | 31.7 ± 2.6 | 0.47 |
Platelet count (×104 cells/mm3) | 13.6 ± 5.7 | 14.7 ± 6.4 | 14.1 ± 5.5 | 13.8 ± 5.4 | 0.71 |
Blood urea nitrogen (mg/dL) | 65.9 ± 13.6 | 66.0 ± 11.3 | 57.5 ± 9.3 | 66.3 ± 12.3 | 0.94 |
Serum creatinine (mg/dL) | 13.1 ± 2.5 | 12.8 ± 2.0 | 12.3 ± 1.9 | 12.4 ± 2.1 | 0.14 |
Serum sodium (mEq/L) | 137.1 ± 1.8 | 138.1 ± 2.0 | 138.8 ± 1.4 | 138.2 ± 2.3 | 0.13 |
Serum potassium (mEq/L) | 5.6 ± 0.5 | 5.2 ± 0.5 | 5.1 ± 0.5 | 5.7 ± 0.5 | 0.40 |
Serum chloride (mEq/L) | 107.6 ± 2.1 | 106.8 ± 2.9 | 109.1 ± 2.2 | 108.4 ± 1.8 | 0.35 |
Serum calcium (mEq/L) | 8.6 ± 0.3 | 8.5 ± 0.5 | 8.6 ± 0.4 | 8.6 ± 0.6 | 0.81 |
Serum inorganic phosphorus (mEq/L) | 4.5 ± 0.6 | 4.9 ± 0.9 | 4.3 ± 0.8 | 5.0 ± 1.0 | 0.27 |
Aspartate transaminase (U/L) | 10.2 ± 3.2 | 11.3 ± 4.4 | 9.2 ± 3.2 | 12.8 ± 5.4 | 0.21 |
Alanine aminotransferase (U/L) | 10.4 ± 3.0 | 10.2 ± 3.3 | 9.8 ± 4.5 | 11.7 ± 4.7 | 0.54 |
Alkaline phosphatase (U/L) | 196.6 ± 53.6 | 217.6 ± 82.6 | 198.0 ± 48.0 | 222.3 ± 67.1 | 0.09 |
Lactate dehydrogenase (U/L) | 155.2 ± 27.1 | 157.6 ± 29.5 | 165.8 ± 23.3 | 165.3 ± 23.1 | 0.30 |
Total protein (g/dL) | 5.9 ± 0.2 | 6.0 ± 0.4 | 5.9 ± 0.4 | 5.9 ± 0.3 | 0.63 |